← Oncology Approval Tracker

FDA DECISION ·

Alymsys

bevacizumab-maly · Amneal Pharmaceuticals

Biosimilar approvalBiosimilarMultiple solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Bevacizumab biosimilar for labeled uses in metastatic colorectal cancer, nonsquamous NSCLC, recurrent glioblastoma, metastatic renal cell carcinoma, and persistent, recurrent or metastatic cervical cancer.

LAMPGEN ANALYSIS

Why it matters

This adds a bevacizumab product for established labeled oncology regimens.

What research teams should watch

Check the product-specific label, treatment partner and formulary authorization for each disease setting.

PRIMARY RECORDS

Sources